Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DTU Publications

2022

Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.

Shields BM. et al, (2022), Nat Med

Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - Authors' reply.

Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 841 - 842

Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol.

Butterly E. et al, (2022), BMJ Open, 12

TriMaster: randomised double-blind crossover trial of a DPP4-inhibitor, SGLT2-inhibitor and thiazolidinedione to evaluate differential glycaemic response to therapy based on obesity and renal function

Hattersley A. et al, (2022)

Endpoints and estimands: understanding trials of weight-loss drugs.

Adler AI., (2022), Nat Med, 28, 2005 - 2006

2021

Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.

Samsky MD. et al, (2021), Atherosclerosis, 338, 1 - 6